Bayram, E. 2024. Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study. SCIENTIFIC REPORTS , vol.14, no.29785 , 1-9.

Bayram, E., (2024). Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study. SCIENTIFIC REPORTS , vol.14, no.29785, 1-9.

Bayram, ERTUĞRUL. "Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study," SCIENTIFIC REPORTS , vol.14, no.29785, 1-9, 2024

Bayram, ERTUĞRUL. "Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study." SCIENTIFIC REPORTS , vol.14, no.29785, pp.1-9, 2024

Bayram, E. (2024) . "Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study." SCIENTIFIC REPORTS , vol.14, no.29785, pp.1-9.

@article{article, author={ERTUĞRUL BAYRAM}, title={Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study}, journal={SCIENTIFIC REPORTS}, year=2024, pages={1-9} }